These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1146 related items for PubMed ID: 28165526

  • 21. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
    Sader HS, Carvalhaes CG, Duncan LR, Flamm RK, Shortridge D.
    J Antimicrob Chemother; 2020 Oct 01; 75(10):2907-2913. PubMed ID: 32653914
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
    Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M.
    J Glob Antimicrob Resist; 2022 Dec 01; 31():98-103. PubMed ID: 35988706
    [Abstract] [Full Text] [Related]

  • 24. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep 01; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

  • 25. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Med Microbiol; 2022 Apr 01; 71(4):. PubMed ID: 35451945
    [Abstract] [Full Text] [Related]

  • 26. Assessment of the In Vitro Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France.
    Viala B, Zaidi FZ, Bastide M, Dumont Y, Le Moing V, Jean-Pierre H, Godreuil S.
    Microb Drug Resist; 2019 Nov 01; 25(9):1325-1329. PubMed ID: 31225764
    [Abstract] [Full Text] [Related]

  • 27. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T, Arena F, Pollini S, Di Pilato V, D'Andrea MM, Henrici De Angelis L, Bassetti M, Rossolini GM, Pseudomonas aeruginosa Working Group.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):664-671. PubMed ID: 29216350
    [Abstract] [Full Text] [Related]

  • 28. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):703-708. PubMed ID: 29244121
    [Abstract] [Full Text] [Related]

  • 29. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
    Pfaller MA, Shortridge D, Harris KA, Garrison MW, DeRyke CA, DePestel DD, Moise PA, Sader HS.
    Int J Infect Dis; 2021 Nov 01; 112():321-326. PubMed ID: 34597763
    [Abstract] [Full Text] [Related]

  • 30. Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
    Shortridge D, Pfaller MA, Streit JM, Flamm RK.
    J Glob Antimicrob Resist; 2020 Jun 01; 21():60-64. PubMed ID: 31648032
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
    Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF.
    Eur J Clin Microbiol Infect Dis; 2024 Jul 01; 43(7):1343-1348. PubMed ID: 38775873
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec 01; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 35. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec 01; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

  • 36. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
    Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.
    Diagn Microbiol Infect Dis; 2019 May 01; 94(1):93-102. PubMed ID: 30642717
    [Abstract] [Full Text] [Related]

  • 37. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 01; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group.
    Eur J Clin Microbiol Infect Dis; 2021 Dec 01; 40(12):2533-2541. PubMed ID: 34291323
    [Abstract] [Full Text] [Related]

  • 40. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bailey AL, Armstrong T, Dwivedi HP, Denys GA, Hindler J, Campeau S, Traczewski M, Humphries R, Burnham CA.
    J Clin Microbiol; 2018 Sep 01; 56(9):. PubMed ID: 29976590
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.